1 of 1
Story summary
- Abbott Laboratories reported Q2 2026 revenue of $12.593 billion, beat estimates, and raised its full-year adjusted EPS outlook to $5.45-$5.60.
- The March 23 2026 acquisition of Exact Sciences for $21 billion added $919 million in cancer-diagnostics revenue and spurred mid-teens growth for Cologuard.
- Net income dropped 48% to $928 million after $658 million in intangible amortization, while Abbott returned $1 billion to shareholders and declared a $0.63 per share dividend.
